Credit Suisse Reinstates Coverage on Amylin Pharmaceuticals (AMLN) at Outperform
Tweet
Share
E-mailGet Alerts AMLN Hot Sheet
Price: $30.98 --0%
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 5 | New: 34
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 5 | New: 34
Join SI Premium – FREE
Credit Suisse reinstates coverage on Amylin Pharmaceuticals (NASDAQ: AMLN) with an Outperform. PT raised from $14 to $22.
For an analyst ratings summary and ratings history on Amylin Pharmaceuticals click here. For more ratings news on Amylin Pharmaceuticals click here.
Shares of Amylin Pharmaceuticals closed at $17.61 yesterday.
For an analyst ratings summary and ratings history on Amylin Pharmaceuticals click here. For more ratings news on Amylin Pharmaceuticals click here.
Shares of Amylin Pharmaceuticals closed at $17.61 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades Bukit Asam Tbk PT (PTBA:IJ) to Underweight
- Adani Ports & Special Economic Zone (ADSEZ:IN) PT Raised to INR2,100 at Macquarie
- Oracle (ORCL) PT Lowered to $200 at Stifel, Buy Rating Maintained
Create E-mail Alert Related Categories
Analyst PT Change, New CoverageRelated Entities
Credit SuisseSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
